Background Severe coronavirus disease 2019 (COVID‐19) is characterized by a
proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may …

Background and aims The coronavirus disease 2019 (COVID-19) number of death cases is
still increasing. One of the comorbidities associated with severe outcome and mortality of …

Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have
been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk …

Although various pharmacologic agents are under active study [1], there are currently no
effective and evidence-based antiviral drugs or drug combinations against severe acute …

Background Statins are a commonly used class of drugs, and reports have suggested that
their use may affect COVID‐19 disease severity and mortality risk. Objective The purpose of …

Preadmission statin therapy is associated with improved outcome in patients hospitalized
with COVID-19. Whether inhibition of inflammation and myocardial injury are in part …

The impact of statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor
blockers (ARBs) on coronavirus disease 2019 (COVID-19) severity and recovery is …

Background Small observational studies have suggested that statin users have a lower risk
of dying with COVID‐19. We tested this hypothesis in a large, population‐based cohort of …

Background: Statins are first-line lipid-lowering agents with tolerable adverse reactions, low
cost, and high availability worldwide. The potent anti-inflammatory, antioxidant, anti …

Summary On 11 March 2020 the World Health Organization (WHO) declared a status of
global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 …